Video
Dr. Koontz gives an overview of ASTRO discussion on new RTOG-0815 data
Author(s):
“I would say what RTOG-0815 has provided is data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.
Video Player is loading.
In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
Related Videos
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Related Content
